IN THE CLAIMS:

Please replace pending claims 12-20 with amended claims 12-20 as follows (a marked-up copy of changes is found in the Appendix of the present amendment):

12. (Amended) The vaccine composition according to claim 10 or claim 11, wherein the at least one particulate immunogen comprises a viral antigen, a bacterial antigen, or a fungal antigen, or a combination thereof.

13. (Amended) The vaccine composition according to claim 10, wherein the at least one particulate immunogen is derived from at least one infective agent which causes a disease which is transmitted by mucosal infection.

14. (Amended) The vaccine composition according to claim 10, wherein the at least one particulate immunogen is characteristic of a micro-organism which causes a disease which is transmitted by mucosal infection.

15. (Amended) The vaccine composition according to claim 10 or claim 11, wherein the at least one particulate immunogen provides immunization against a disease which is transmitted by mucosal infection.

16. (Amended) The vaccine composition according to claim 15, wherein the at least one particulate immunogen comprises at least one influenza antigen.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

17. (Amended) A method for the induction of a systemic immunoglobulin response against at least one immunogen in a human or animal host in need of such induction, comprising:

administering to mucosal tissue of the host said at least one immunogen in particulate form and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli,* wherein said B subunits are free of A subunit and toxic LT holotoxin, and wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said induction.

18. (Amended) A method for the induction of a common mucosal immune response against at least one immunogen in a human or animal host in need of such induction, comprising:

administering to mucosal tissue of the host said at least one immunogen in particulate form and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli,* wherein said B subunits are free of A subunit and toxic LT holotoxin, and wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said induction.

19. (Amended) A method of preparing a vaccine for the induction of a systemic immunoglobulin response against at least one immunogen in a human or animal host upon mucosal administration of said vaccine, comprising:

combining said at least one immunogen in particulate form and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli,* wherein said B

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

subunits are free of A subunit and toxic LT holotoxin, and wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said induction.

20. (Amended) A method of preparing a vaccine for the induction of a common mucosal immune response against at least one immunogen in a human or animal host upon local mucosal administration of said vaccine, comprising:

combining said at least one immunogen in particulate form and an adjuvanting amount of B subunits of heat-labile enterotoxin characteristic of *E. coli,* wherein said B subunits are free of A subunit and toxic LT holotoxin, and wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said induction.

Please add new claims 24-26 as follows:

24. (New) The vaccine according to claim 21, wherein the at least one particulate immunogen comprises at least one influenza antigen.

25. (New) The vaccine according to claim 22, wherein the at least one particulate immunogen comprises at least one influenza antigen.

26. (New) The vaccine according to claim 23, wherein the at least one immunogen comprises at least one influenza antigen.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com